View ValuationJerusalem Pharmaceuticals 将来の成長Future 基準チェック /06現在、 Jerusalem Pharmaceuticalsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長14.9%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesBoard Change • May 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 11 non-independent directors. Director Haitham Mohammed Masrouji was the last director to join the board, commencing their role in 2026. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Apr 18Jerusalem Pharmaceuticals Co. Ltd. Announces Board ChangesJerusalem Pharmaceuticals Co. Ltd. announced that at the ordinary General Assembly meeting held on April 15, 2026, Approval of the resignation of Dr. Samir Al-Khatib from the Board of Directors and was replaced by Dr. Haitham Masrouji as a member of the Board of Directors.お知らせ • Mar 31Jerusalem Pharmaceuticals Co. Ltd. to Report Q1, 2026 Results on Apr 15, 2026Jerusalem Pharmaceuticals Co. Ltd. announced that they will report Q1, 2026 results on Apr 15, 2026お知らせ • Mar 18Jerusalem Pharmaceuticals Co. Ltd. announces Annual dividendJerusalem Pharmaceuticals Co. Ltd. announced Annual dividend of USD 0.1500 per share, ex-date on April 16, 2026 and record date on April 19, 2026.お知らせ • Mar 12Jerusalem Pharmaceuticals Co. Ltd., Annual General Meeting, Apr 15, 2026Jerusalem Pharmaceuticals Co. Ltd., Annual General Meeting, Apr 15, 2026. Location: ramallah Palestinian Authorityお知らせ • Feb 25Jerusalem Pharmaceuticals Co. Ltd. to Report Fiscal Year 2025 Results on Mar 10, 2026Jerusalem Pharmaceuticals Co. Ltd. announced that they will report fiscal year 2025 results on Mar 10, 2026お知らせ • Dec 17Jerusalem Pharmaceuticals Co. Ltd. to Report First Half, 2025 Results on Dec 29, 2025Jerusalem Pharmaceuticals Co. Ltd. announced that they will report first half, 2025 results on Dec 29, 2025Board Change • Jun 10No independent directorsThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 8 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). Deputy Chairman Iyad Masrouji was the last director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.お知らせ • Apr 15Jerusalem Pharmaceuticals Co. Ltd., Annual General Meeting, Apr 29, 2025Jerusalem Pharmaceuticals Co. Ltd., Annual General Meeting, Apr 29, 2025. Location: ramallah Palestinian Authorityお知らせ • Mar 22Jerusalem Pharmaceuticals Co. Ltd. announces Annual dividend, payable on June 29, 2025Jerusalem Pharmaceuticals Co. Ltd. announced Annual dividend of USD 0.0800 per share payable on June 29, 2025, ex-date on April 30, 2025 and record date on May 04, 2025.お知らせ • Mar 21Jerusalem Pharmaceuticals Co. Ltd., Annual General Meeting, Mar 19, 2025Jerusalem Pharmaceuticals Co. Ltd., Annual General Meeting, Mar 19, 2025. Location: ramallah Palestinian AuthorityBoard Change • Feb 12No independent directorsThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 8 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). Deputy Chairman Iyad Masrouji was the last director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Reported Earnings • Aug 16Second quarter 2024 earnings released: EPS: US$0.053 (vs US$0.083 in 2Q 2023)Second quarter 2024 results: EPS: US$0.053 (down from US$0.083 in 2Q 2023). Revenue: US$8.68m (down 7.0% from 2Q 2023). Net income: US$953.3k (down 36% from 2Q 2023). Profit margin: 11% (down from 16% in 2Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 7% per year whereas the company’s share price has increased by 10% per year.Reported Earnings • Jun 16First quarter 2024 earnings released: EPS: US$0.015 (vs US$0.082 in 1Q 2023)First quarter 2024 results: EPS: US$0.015 (down from US$0.082 in 1Q 2023). Revenue: US$7.90m (down 16% from 1Q 2023). Net income: US$273.0k (down 82% from 1Q 2023). Profit margin: 3.5% (down from 16% in 1Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth.Upcoming Dividend • May 14Upcoming dividend of US$0.10 per shareEligible shareholders must have bought the stock before 21 May 2024. Payment date: 21 July 2024. Payout ratio is a comfortable 31% and this is well supported by cash flows. Trailing yield: 2.6%. Lower than top quartile of Palestinian Territory, Occupied dividend payers (6.0%). Higher than average of industry peers (1.9%).Board Change • Jan 15No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • Nov 04No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Reported Earnings • Aug 12Second quarter 2023 earnings released: EPS: US$0.083 (vs US$0.063 in 2Q 2022)Second quarter 2023 results: EPS: US$0.083 (up from US$0.063 in 2Q 2022). Revenue: US$9.33m (down 10% from 2Q 2022). Net income: US$1.49m (up 33% from 2Q 2022). Profit margin: 16% (up from 11% in 2Q 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth.Board Change • Jul 11No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • May 31No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Upcoming Dividend • Apr 11Upcoming dividend of US$0.15 per share at 2.9% yieldEligible shareholders must have bought the stock before 18 April 2023. Payment date: 18 June 2023. Payout ratio is a comfortable 28% and this is well supported by cash flows. Trailing yield: 2.9%. Lower than top quartile of Palestinian Territory, Occupied dividend payers (6.1%). Higher than average of industry peers (1.8%).Board Change • Jan 18No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • Nov 17No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • Oct 07No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • Jun 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • May 05No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Upcoming Dividend • Apr 05Upcoming dividend of US$0.12 per shareEligible shareholders must have bought the stock before 12 April 2022. Payment date: 12 June 2022. Payout ratio is a comfortable 34% and this is well supported by cash flows. Trailing yield: 3.8%. Lower than top quartile of Palestinian Territory, Occupied dividend payers (5.1%). Higher than average of industry peers (1.7%).Board Change • Jan 10No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. No highly experienced directors. No independent directors (11 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Upcoming Dividend • May 23Upcoming dividend of US$0.08 per shareEligible shareholders must have bought the stock before 30 May 2021. Payment date: 26 July 2021. Trailing yield: 3.4%. Lower than top quartile of Palestinian Territory, Occupied dividend payers (6.0%). Higher than average of industry peers (1.4%).Is New 90 Day High Low • Mar 11New 90-day high: US$2.88The company is up 3.0% from its price of US$2.80 on 02 December 2020. The Palestinian Territory, Occupied market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 3.0% over the same period.Is New 90 Day High Low • Dec 20New 90-day high: US$2.85The company is up 14% from its price of US$2.50 on 22 September 2020. The Palestinian Territory, Occupied market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is flat over the same period.Is New 90 Day High Low • Nov 12New 90-day high: US$2.60The company is up 5.0% from its price of US$2.47 on 12 August 2020. The Palestinian Territory, Occupied market is down 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 6.0% over the same period.Is New 90 Day High Low • Oct 22New 90-day high: US$2.58The company is up 7.0% from its price of US$2.41 on 21 July 2020. The Palestinian Territory, Occupied market is down 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 6.0% over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Jerusalem Pharmaceuticals は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測PLSE:JPH - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2025491014N/A9/30/2025481058N/A6/30/2025448811N/A3/31/20254271216N/A12/31/2024405912N/A9/30/202437414N/A6/30/202438547N/A3/31/202438636N/A12/31/202340779N/A9/30/20234391517N/A6/30/20234481415N/A3/31/20234581617N/A12/31/20224671617N/A9/30/20224681113N/A6/30/20224781113N/A3/31/202247746N/A12/31/202146746N/A9/30/202141457N/A6/30/202140424N/A3/31/202137346N/A12/31/202036402N/A9/30/202036502N/A6/30/202035513N/A3/31/202035613N/A12/31/201934502N/A9/30/2019324N/A2N/A6/30/2019324N/A5N/A3/31/2019315N/A5N/A12/31/2018315N/A4N/A9/30/2018326N/A9N/A6/30/2018286N/A6N/A3/31/2018306N/A5N/A12/31/2017306N/A5N/A9/30/2017285N/A2N/A6/30/2017305N/A2N/A3/31/2017285N/A1N/A12/31/2016263N/A2N/A9/30/2016241N/A1N/A6/30/2016241N/A4N/A3/31/2016241N/A2N/A12/31/2015262N/A2N/A9/30/2015264N/A1N/A6/30/2015263N/A1N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: JPHの予測収益成長が 貯蓄率 ( 15.1% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: JPHの収益がPS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: JPHの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: JPHの収益がPS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: JPHの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: JPHの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/05 13:01終値2026/06/04 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Jerusalem Pharmaceuticals Co. Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Board Change • May 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 11 non-independent directors. Director Haitham Mohammed Masrouji was the last director to join the board, commencing their role in 2026. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 18Jerusalem Pharmaceuticals Co. Ltd. Announces Board ChangesJerusalem Pharmaceuticals Co. Ltd. announced that at the ordinary General Assembly meeting held on April 15, 2026, Approval of the resignation of Dr. Samir Al-Khatib from the Board of Directors and was replaced by Dr. Haitham Masrouji as a member of the Board of Directors.
お知らせ • Mar 31Jerusalem Pharmaceuticals Co. Ltd. to Report Q1, 2026 Results on Apr 15, 2026Jerusalem Pharmaceuticals Co. Ltd. announced that they will report Q1, 2026 results on Apr 15, 2026
お知らせ • Mar 18Jerusalem Pharmaceuticals Co. Ltd. announces Annual dividendJerusalem Pharmaceuticals Co. Ltd. announced Annual dividend of USD 0.1500 per share, ex-date on April 16, 2026 and record date on April 19, 2026.
お知らせ • Mar 12Jerusalem Pharmaceuticals Co. Ltd., Annual General Meeting, Apr 15, 2026Jerusalem Pharmaceuticals Co. Ltd., Annual General Meeting, Apr 15, 2026. Location: ramallah Palestinian Authority
お知らせ • Feb 25Jerusalem Pharmaceuticals Co. Ltd. to Report Fiscal Year 2025 Results on Mar 10, 2026Jerusalem Pharmaceuticals Co. Ltd. announced that they will report fiscal year 2025 results on Mar 10, 2026
お知らせ • Dec 17Jerusalem Pharmaceuticals Co. Ltd. to Report First Half, 2025 Results on Dec 29, 2025Jerusalem Pharmaceuticals Co. Ltd. announced that they will report first half, 2025 results on Dec 29, 2025
Board Change • Jun 10No independent directorsThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 8 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). Deputy Chairman Iyad Masrouji was the last director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
お知らせ • Apr 15Jerusalem Pharmaceuticals Co. Ltd., Annual General Meeting, Apr 29, 2025Jerusalem Pharmaceuticals Co. Ltd., Annual General Meeting, Apr 29, 2025. Location: ramallah Palestinian Authority
お知らせ • Mar 22Jerusalem Pharmaceuticals Co. Ltd. announces Annual dividend, payable on June 29, 2025Jerusalem Pharmaceuticals Co. Ltd. announced Annual dividend of USD 0.0800 per share payable on June 29, 2025, ex-date on April 30, 2025 and record date on May 04, 2025.
お知らせ • Mar 21Jerusalem Pharmaceuticals Co. Ltd., Annual General Meeting, Mar 19, 2025Jerusalem Pharmaceuticals Co. Ltd., Annual General Meeting, Mar 19, 2025. Location: ramallah Palestinian Authority
Board Change • Feb 12No independent directorsThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 8 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). Deputy Chairman Iyad Masrouji was the last director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Reported Earnings • Aug 16Second quarter 2024 earnings released: EPS: US$0.053 (vs US$0.083 in 2Q 2023)Second quarter 2024 results: EPS: US$0.053 (down from US$0.083 in 2Q 2023). Revenue: US$8.68m (down 7.0% from 2Q 2023). Net income: US$953.3k (down 36% from 2Q 2023). Profit margin: 11% (down from 16% in 2Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 7% per year whereas the company’s share price has increased by 10% per year.
Reported Earnings • Jun 16First quarter 2024 earnings released: EPS: US$0.015 (vs US$0.082 in 1Q 2023)First quarter 2024 results: EPS: US$0.015 (down from US$0.082 in 1Q 2023). Revenue: US$7.90m (down 16% from 1Q 2023). Net income: US$273.0k (down 82% from 1Q 2023). Profit margin: 3.5% (down from 16% in 1Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth.
Upcoming Dividend • May 14Upcoming dividend of US$0.10 per shareEligible shareholders must have bought the stock before 21 May 2024. Payment date: 21 July 2024. Payout ratio is a comfortable 31% and this is well supported by cash flows. Trailing yield: 2.6%. Lower than top quartile of Palestinian Territory, Occupied dividend payers (6.0%). Higher than average of industry peers (1.9%).
Board Change • Jan 15No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Nov 04No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Reported Earnings • Aug 12Second quarter 2023 earnings released: EPS: US$0.083 (vs US$0.063 in 2Q 2022)Second quarter 2023 results: EPS: US$0.083 (up from US$0.063 in 2Q 2022). Revenue: US$9.33m (down 10% from 2Q 2022). Net income: US$1.49m (up 33% from 2Q 2022). Profit margin: 16% (up from 11% in 2Q 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth.
Board Change • Jul 11No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • May 31No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Upcoming Dividend • Apr 11Upcoming dividend of US$0.15 per share at 2.9% yieldEligible shareholders must have bought the stock before 18 April 2023. Payment date: 18 June 2023. Payout ratio is a comfortable 28% and this is well supported by cash flows. Trailing yield: 2.9%. Lower than top quartile of Palestinian Territory, Occupied dividend payers (6.1%). Higher than average of industry peers (1.8%).
Board Change • Jan 18No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Nov 17No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Oct 07No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Jun 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • May 05No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Upcoming Dividend • Apr 05Upcoming dividend of US$0.12 per shareEligible shareholders must have bought the stock before 12 April 2022. Payment date: 12 June 2022. Payout ratio is a comfortable 34% and this is well supported by cash flows. Trailing yield: 3.8%. Lower than top quartile of Palestinian Territory, Occupied dividend payers (5.1%). Higher than average of industry peers (1.7%).
Board Change • Jan 10No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. No highly experienced directors. No independent directors (11 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Upcoming Dividend • May 23Upcoming dividend of US$0.08 per shareEligible shareholders must have bought the stock before 30 May 2021. Payment date: 26 July 2021. Trailing yield: 3.4%. Lower than top quartile of Palestinian Territory, Occupied dividend payers (6.0%). Higher than average of industry peers (1.4%).
Is New 90 Day High Low • Mar 11New 90-day high: US$2.88The company is up 3.0% from its price of US$2.80 on 02 December 2020. The Palestinian Territory, Occupied market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 3.0% over the same period.
Is New 90 Day High Low • Dec 20New 90-day high: US$2.85The company is up 14% from its price of US$2.50 on 22 September 2020. The Palestinian Territory, Occupied market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is flat over the same period.
Is New 90 Day High Low • Nov 12New 90-day high: US$2.60The company is up 5.0% from its price of US$2.47 on 12 August 2020. The Palestinian Territory, Occupied market is down 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 6.0% over the same period.
Is New 90 Day High Low • Oct 22New 90-day high: US$2.58The company is up 7.0% from its price of US$2.41 on 21 July 2020. The Palestinian Territory, Occupied market is down 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 6.0% over the same period.